A large Nature Medicine study inferred cell-type aging from plasma proteins. The model predicted risk at population level, but it is not a diagnosis or validated clinic treatment engine.
ER-100 has entered a Phase 1 eye-disease trial. This is a safety milestone for partial epigenetic reprogramming, not approval or proof of whole-body age reversal.
A buyer-focused guide to epigenetic testing at longevity clinics: when biological-age clocks add useful context, when they become sales theater, and what to ask before paying.
A practical 2026 guide to biological age testing in longevity clinics: epigenetic clocks, proteomic and multi-omics clocks, imaging-derived organ age, inflammatory markers, and the clinical tests that actually change decisions.
Biological age tests can disagree because clocks use different targets, datasets, assays, and endpoints. This guide explains what accuracy means and what a result can actually change.
Therapeutic plasma exchange is established for selected diseases, not for extending healthy lifespan. A 42-person trial changed epigenetic clocks, but did not test fewer diseases, better function, or longer life.
